Rgenta Therapeutics Inc. has announced preclinical data on RGT-0474060, an oral PMS1 inhibitor for Huntington’s disease. RGT-0474060 is an orally bioavailable small molecule designed to inhibit PMS1 RNA and protein expression, to modulate splicing of CAG repeat expansion known to cause Huntington’s disease.